Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.

Trial Details

NCT ID
NCT04405401
Phase
PHASE2
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SABR
  • Standard of care
Locations (sample)
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Age ≥18 years
  • Metastatic NSCLC enrolled in our CRCHUM Lung Cancer Registry and co-enrolled to the PERa registry
  • Ability to provide written informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-3

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →